资料显示，启迪药业集团股份公司位于湖南省衡阳市雁峰区罗金桥1号(雁峰区工业项目集聚区)总部办 公楼，成立日期1993年11月12日，上市日期1996年1月19日，公司主营业务涉及研究、开发中国中药传 统秘方、验方和西药制剂,生产古汉养生精(口服液、片剂)、养心定悸颗粒、健肾壮腰丸等中成药以及大 容量注射剂、原料药、五维赖氨酸口服溶液等西药制剂。主营业务收入构成为：中药公司及营销公司产 品79.43%，广东先通公司产品14.28%，其他5.98%，制药公司产品0.31%。 启迪药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：智慧医疗、微盘股、小盘、 中药等。 截至9月30日，启迪药业股东户数1.76万，较上期增加17.25%；人均流通股13587股，较上期减少 14.71%。2025年1月-9月，启迪药业实现营业收入2.25亿元，同比增长3.97%；归母净利润-1482.06万 元，同比增长47.91%。 11月25日，启迪药业盘中上涨2.03%，截至10:40，报11.56元/股，成交1503.50万元，换手率0.55%，总 市值27.68亿元。 资金流向方面，主力资金净流入58.48万元，大 ...

Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]

启迪药业集团股份公司 （经公司2025年第二次临时股东会审议通过） | 第十章 | 合并、分立、增资、减资、解散和清算 39 | | | --- | --- | --- | | 第一节 | 合并、分立、增资和减资 39 | | | 第二节 | 解散和清算 | 40 | | 第十一章 | 修改章程 | 42 | | 第十二章 | 附则 | 42 | 第一章 总则 第三条 公司于 1995 年 12 月 25 日经中国证券监督管理委员会（以下简称"中国证 监会"）批准，首次向社会公众发行人民币普通股 1,500 万股(含内部职工股 500 万股)， 于 1996 年 1 月 19 日在深圳证券交易所上市。 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行为， 充分发挥中国共产党在公司的领导核心作用，根据《中华人民共和国公司法》(以下简 称《公司法》)、《中华人民共和国证券法》(以下简称《证券法》)、《中国共产党章程》 （以下简称《党章》）和其他有关规定，制定本章程。 第四条 公司注册名称： 中文全称：启迪药业集团股份公司 | 第一章 | 总则 | 3 | | --- | --- | --- | ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-056 启迪药业集团股份公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 假记载、误导性陈述或重大遗漏。 记载、误导性陈述或重大遗漏。 特别提示 1、本次会议未出现否决提案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 6、会议的召开符合《公司法》《股票上市规则》《上市公司股东大会规范 意见》及公司章程的规定。2025年10月28日，公司召开了第十届董事会临时会议， 审议通过了《关于召开2025年第二次临时股东大会的议案》。本次会议的通知刊 登于2025年10月30日《中国证券报》《证券时报》《上海证券报》和巨潮资讯网 一、会议召开的情况 1、召开时间： （1）现场会议时间：2025 年 11 月 18 日(星期二)下午 14:30。 （2）网络投票时间：2025 年 11 月 18 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 11 月 18 日上午 9:15—9:25,9: ...

湖南启元律师事务所 关于 启迪药业集团股份公司 2025年第二次临时股东大会的 法律意见书 二〇二五年十一月 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410005 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 1、刊登在中国证券监督管理委员会（以下简称"中国证监会"）指定媒体 和巨潮咨询网站（http://www.cninfo.com.cn/）的与本次股东大会有关的通知等公 告事项； 2、出席会议的股东或其代理人的身份证明文件、持股证明文件、授权委托 书等； 致：启迪药业集团股份公司 湖南启元律师事务所（以下简称"本所"）受启迪药业集团股份公司（以下 简称"公司"）委托，指派本所律师出席了公司 2025 年第二次临时股东大会（以 下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员 及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表 本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（ ...

Group 1 - A total of 18 stocks experienced a price increase of over 40% during the week of November 10 to November 14, with 11 stocks rising over 50% [1] - Huasheng Lithium Battery topped the weekly gainers with a remarkable increase of 79.61% [1] - Other notable gainers included Haike Xinyuan, Jindike, and Furui Shares, with weekly increases of 71.38%, 61.65%, and 61.23% respectively [1] Group 2 - On the downside, 5 stocks recorded a decline of over 20% during the same week, with *ST Changyao leading the losses at 33.62% [1] - Haitan Shares and Degute experienced declines of 29.01% and 24.65% respectively [1]

*ST元成11月11日称，因公司股票出现连续20个交易日每日股票收盘总市值均低于5亿元，已触及 规定的交易类退市指标，公司股票自11日开市起停牌。这意味着公司将面临退市。 今年以来，监管层对上市公司的违法违规行为严厉打压。上周末，就有5家公司或公司相关方被立 案调查。根据同花顺统计，截至11月11日，年内共有60家A股公司被立案调查。从被立案的原因来看， 大多数涉嫌信息披露违规，也有少数公司因财务造假被立案。其中，五成被立案公司为ST个股。 记者注意到，被立案公司股价均大跌。11月7日晚，八一钢铁、*ST长药公告称，公司于当日收到 证监会下发的《立案告知书》，证监会决定对公司立案。其中，八一钢铁涉嫌信息披露违法违规、*ST 长药则涉嫌定期报告等财务数据虚假记载。受此利空冲击，八一钢铁、*ST长药11月10日股价双双跌 停。 除了上市公司本身，还有部分高管也被立案调查。如北交所公司骑士乳业7月初公告称，因期货投 资巨亏未及时披露，涉嫌信息披露违法违规，公司及相关当事人董事长兼总经理党涌涛、董秘陈勇、财 务负责人王喜临均被立案调查。仅半个多月后，公司及相关人员收到行政处罚决定书，内蒙古证监局决 定对公司责令改正， ...

Core Viewpoint - Qidi Pharmaceutical announced the cancellation of a proposal to change its name to "Guhan Health Industry Group Co., Ltd." due to the lack of approval from market supervision authorities [1] Group 1 - The company's board of directors held a temporary meeting on September 16, where the decision to cancel the name change proposal was made [1] - The company emphasized that any future name change plans will comply with legal and regulatory requirements for timely information disclosure [1] - "Guhan," as an established brand under the company, has built a strong reputation and goodwill in the market [1] Group 2 - The company plans to leverage the "Guhan" brand as a key resource to enhance research and development as well as market promotion efforts [1] - The focus on the "Guhan" brand aims to further improve performance and brand influence [1]

Group 1 - Great Wall Technology has terminated the planning of control change matters and will resume trading on November 10, 2025 [2] - The actual controllers of Great Wall Technology were in discussions for a share transfer that could lead to a change in control, but they decided to terminate the planning due to a lack of consensus on core issues [2] Group 2 - Eight One Steel and other companies or shareholders are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [3] - Eight One Steel received a notice from the CSRC regarding the investigation, stating that their production and operations remain normal and will not be significantly affected [3] Group 3 - ST Chang Pharmaceutical has been investigated by the CSRC for suspected false reporting of financial data, which could lead to mandatory delisting if found guilty of major violations [4] - Intercontinental Oil and Gas is also under investigation, but the investigation pertains to a shareholder and does not affect the company's operations [4] Group 4 - Tianyi New Materials has agreed to undergo pre-restructuring due to creditor applications, which is expected to improve the chances of successful restructuring [6] - The pre-restructuring process will facilitate early communication with creditors and potential investors [6] Group 5 - Suzhou Planning intends to acquire 100% of Dongjin Aviation Technology through a combination of share issuance and cash payment, with a transaction price of 250 million yuan [7] - This acquisition aims to create a competitive integrated solution in air traffic management, addressing industry pain points and aligning with the development of the low-altitude economy [7] Group 6 - Del Shares plans to acquire 100% of Aizhuo Intelligent Technology through share issuance and will raise matching funds from specific investors [8] - The transaction has been reviewed and approved by the Shenzhen Stock Exchange's merger and reorganization review committee [8] Group 7 - Degute has decided to terminate its major asset restructuring transaction due to difficulties in forming a satisfactory plan within the effective time window [9] - The termination requires further negotiations and internal approval processes from the involved parties [9] Group 8 - Aerospace Hanyu's subsidiary has won a bid for a project worth approximately 246.3 million yuan, which is expected to positively impact the company's performance [11] - Huachang Communications has elected a new chairman, which may influence the company's strategic direction [11] Group 9 - Maolai Optical has received approval from the CSRC to issue convertible bonds to unspecified investors [12] - Tianchen Medical has adjusted its share repurchase plan, increasing the maximum repurchase price and total amount [12] Group 10 - Jiangsu Youxian's controlling shareholder plans to increase its stake in the company by investing between 100 million and 150 million yuan [21] - Jian Ke Institute plans to reduce its holdings by up to 1,466,600 shares [21]

Mergers and Acquisitions - Zhengzhou Bank plans to acquire 49% of the shares held by other shareholders of Xun County Zhengyin Village Bank for cash and will absorb and merge it into a branch of Zhengzhou Bank [1] - Sichuan Road and Bridge intends to acquire the bridge component asset group of New筑股份 for 628 million yuan, which constitutes a related party transaction [2] - Leike Defense has decided to acquire 24.4004% equity from minority shareholders of its subsidiary Yao Yun Technology for a transaction price based on the assessed value, totaling 117 million yuan [3] Shareholding Changes - Fuzhou Technology's controlling shareholder plans to reduce its stake by up to 2%, amounting to no more than 9.405 million shares [4] - Xinlong Holdings' shareholder Hainan Zhuhua plans to reduce its stake by up to 3%, which is no more than 16.15 million shares [5] - Jiangsu Cable's controlling shareholder intends to increase its stake by 100 million to 150 million yuan within 12 months, with a maximum purchase price of 4 yuan per share [6] Regulatory Issues - *ST Chang Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected false reporting of financial data [7] - Continental Oil and Gas's shareholder is being investigated for failing to halt trading when their combined shareholding reached 5% [8] - Meihua Biological's controlling shareholder has been sentenced to three years in prison, suspended for five years, for manipulating the securities market [9] - Bayi Steel is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure regulations [10]